Go Pro
→ The end of AI data centers coming? (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$40.50
$40.16
$12.74
▼
$40.56
$6.27B1.112.15 million shsN/A
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.00%0.00%0.00%+1.86%+85.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
$40.50
$40.16
$12.74
▼
$40.56
$6.27B1.112.15 million shsN/A
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.00%0.00%0.00%+1.86%+85.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
2.21
Hold$41.332.06% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/A$3.92 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
0.23
9.53
9.53

Institutional Ownership

CompanyInstitutional Ownership
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
82.01%

Insider Ownership

CompanyInsider Ownership
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
4.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Centessa Pharmaceuticals PLC Sponsored ADR stock logo
CNTA
Centessa Pharmaceuticals
200154.73 million148.40 millionOptionable

Recent News About These Companies

Centessa Pharmaceuticals (NASDAQ:CNTA): Small-Cap Biotech Story In Focus
August 17, 2026  |  kalkinemedia.comK
Why Is Centessa (NASDAQ:CNTA) on Watch Ahead of Results?
August 17, 2026  |  kalkinemedia.comK
Global UAV Announces Proposed Acquisition of Nexus Peptide Sciences Inc.
July 27, 2026  |  newsfilecorp.comN
Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315602/0/en/acquisition-of-centessa-by-lilly-approved-by-the-high-court-of-justice-of-england-and-wales.html
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
June 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/actinium-appoints-accomplished-oncology-expert-steffen-heeger-md-msc-as-chief-medical-officer-to-drive-rejuvenated-pipeline-development-302786574.html
Are CNTA, WSR, GDOT Obtaining Fair Deals for their Shareholders?
May 12, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/are-cnta-wsr-gdot-obtaining-fair-deals-for-their-shareholders-302768946.html
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA
May 11, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260511798910/en/centessa-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-centessa-pharmaceuticals-plc---cnta/
Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge?
May 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/too-consider-centessa-pharmaceuticals-cnta-191226949.html
Centessa Pharmaceuticals plc (CNTA)
May 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/CNTA/
Wells Fargo downgrades Centessa Pharmaceuticals plc - Depositary Receipt (CNTA)
April 21, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/wells-fargo-downgrades-centessa-pharmaceuticals-plc-depositary-receipt-cnta/ar-AA21n9JO
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?
April 12, 2026  |  marketwatch.comhttps://www.marketwatch.com/press-release/are-apls-cnta-kzr-obtaining-fair-deals-for-their-shareholders-1dde68ff
Shareholder Alert: The Ademi Firm investigates whether Centessa Pharmaceuticals plc is obtaining a Fair Price for Public Shareholders
April 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/07/3269006/884/en/shareholder-alert-the-ademi-firm-investigates-whether-centessa-pharmaceuticals-plc-is-obtaining-a-fair-price-for-public-shareholders.html
Guggenheim downgrades Centessa Pharmaceuticals plc - Depositary Receipt (CNTA)
April 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/guggenheim-downgrades-centessa-pharmaceuticals-plc-depositary-receipt-cnta/ar-AA2039V5
Leerink Partners downgrades Centessa Pharmaceuticals plc - depositary receipt (CNTA)
April 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/leerink-partners-downgrades-centessa-pharmaceuticals-plc-depositary-receipt-cnta/ar-AA1ZZ6nZ
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Centessa Pharmaceuticals plc (NASDAQ: CNTA)
April 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/shareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-centessa-pharmaceuticals-plc-nasdaq-cnta-302731971.html
LLY to Buy Neuroscience Biotech Centessa Pharmaceuticals in $7.8B Deal
April 1, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2893006/lly-to-buy-neuroscience-biotech-centessa-pharmaceuticals-in-7-8b-deal?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2893006
Needham downgrades Centessa Pharmaceuticals plc - depositary receipt (CNTA)
April 1, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/needham-downgrades-centessa-pharmaceuticals-plc-depositary-receipt-cnta/ar-AA1ZSotc
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8B in Sleep Drug Mega-Deal, CNTA Stock Soaring 45%
March 31, 2026  |  ibtimes.comI
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plc - CNTA
March 31, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260331352671/en/centessa-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-centessa-pharmaceuticals-plc---cnta/
Eli Lilly stock rises after $7.8B Centessa deal—bet on sleep drugs
March 31, 2026  |  invezz.comI

New MarketBeat Followers Over Time

Media Sentiment Over Time

Centessa Pharmaceuticals stock logo

Centessa Pharmaceuticals NASDAQ:CNTA

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas